𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐨𝐮𝐫 𝐧𝐞𝐰 𝐬𝐭𝐚𝐭𝐞-𝐨𝐟-𝐭𝐡𝐞-𝐚𝐫𝐭 𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 (𝐐𝐂) 𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐢𝐞𝐬 The pharmaceutical and biotech industries rely heavily on advanced analytical techniques to streamline drug development and manufacturing processes. Careful selection and optimization of analytical methods are crucial for 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗯𝘆 𝗗𝗲𝘀𝗶𝗴𝗻 (𝗤𝗯𝗗) product development, regulatory compliance, and overall efficiency. Advaxia Biologics exemplifies how the optimization of analytical methods can significantly enhance and accelerate drug development from preclinical to clinical phases. With our newly built and 𝗚𝗠𝗣-𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗤𝗖 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, designed to meet the highest standards of safety and efficiency, we’re able to offer a broad range of 𝗽𝗿𝗼𝗱𝘂𝗰𝘁-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗚𝗠𝗣 𝗮𝘀𝘀𝗮𝘆𝘀 applicable to various viral vectors, biologics, and gene therapy products (testing for clinical studies and commercial batches) including: // Digital/Quantitative/Nested PCR methods // Restriction analysis // Western blot // Cellular assays (e.g., immunostaining methods and ELISA) // UPLC // Compendial methods (Container closure integrity, Dynamic light scattering, Mycoplasma detection by PCR, Endotoxin (LAL) testing, Osmolality measurement, Conductivity, TOC, pH, Bioburden) Additionally, we perform 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲𝗱/𝗶𝗻-𝘂𝘀𝗲 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 studies according to ICH Q1A and Q5C. Our new QC facility (𝘀𝘄𝗶𝗽𝗲 𝗳𝗼𝗿 𝗯𝗲𝗵𝗶𝗻𝗱-𝘁𝗵𝗲-𝘀𝗰𝗲𝗻𝗲𝘀 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀) is equipped with the latest technology and meticulously planned to support your GMP testing as well as R&D needs. Get in touch to discover more. #biologics #genetherapy #gmp #cdmo #ADVAXIA
Advaxia Biologics
Fabbricazione di prodotti farmaceutici
Pomezia, Rome 650 follower
Advaxia Biologics is a cGMP Contract Development & Manufacturing Organisation (CDMO), located in Italy.
Chi siamo
Advaxia Biologics (formerly Advent), part of the IRBM group, is a cGMP Contract Development & Manufacturing Organisation (CDMO), located near Rome (Pomezia) Italy, compliant with the regulatory guidelines of the EMA, MHRA and FDA. Advaxia’s integrated contract services portfolio includes outstanding support in the areas of analytical method development, process development/validation, in-process assay development & qualification, GMP Manufacture, full QC product release, ICH Stability and cell banking. Advaxia is dedicated to the development and production of clinical lots of recombinant adenoviruses to support clinical trials for vaccine and gene therapy applications. The Advaxia team has built an outstanding track record in the production of clinical lots for many infectious diseases, including Ebola, HIV and supported the global effort to expedite delivery of a COVID-19 vaccine.
- Sito Web
-
https://www.advaxia.com
Link esterno per Advaxia Biologics
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- 51-200 dipendenti
- Sede principale
- Pomezia, Rome
- Tipo
- Società privata non quotata
- Data di fondazione
- 2010
- Settori di competenza
- Adenovirus, Process Development, cGMP Manufacture, Viral Vectors, Vaccines, Analytical Development, Quality Control, Stability, Cell line Development e Cell-based Assays
Località
-
Principale
Via Pontina km 30.600
c/o IRBM Science Park
Pomezia, Rome 00071, IT
Dipendenti presso Advaxia Biologics
Aggiornamenti
-
The Bio International Convention in San Diego is a month away, so if you are attending, reach out to our team to set a meeting. Visit the Advaxia events page (https://lnkd.in/gX4aupER) or follow the link below to the Bio Partnering portal. https://lnkd.in/gYvxpA3c #BIO2024 #ADVAXIA
-
-
Advaxia Biologics ha diffuso questo post
𝗔𝗱𝘃𝗮𝘅𝗶𝗮 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝗛𝗶𝗴𝗵 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗥𝗮𝘁𝗶𝗻𝗴: 𝗔 𝗦𝘁𝗲𝗽 𝗙𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗼𝘂𝗿 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗝𝗼𝘂𝗿𝗻𝗲𝘆 We are proud to share that we’ve been awarded an impressive 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗿𝗮𝘁𝗶𝗻𝗴, marking a significant milestone in our commitment to sustainability. This certification is a testament to @Advaxia's dedication to 𝗘𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹, 𝗦𝗼𝗰𝗶𝗮𝗹, 𝗮𝗻𝗱 𝗚𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 (𝗘𝗦𝗚) 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲, an essential component of modern business practices, especially within the pharmaceutical and biotech industries where sustainable and ethical practices can greatly reduce environmental impact. Studies, including one from the Journal of Sustainable Finance & Investment, show that 𝗳𝗶𝗿𝗺𝘀 𝘄𝗶𝘁𝗵 𝘀𝘁𝗿𝗼𝗻𝗴 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹 𝗽𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗰𝗮𝗻 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲𝗶𝗿 𝗰𝗮𝗿𝗯𝗼𝗻 𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 𝗯𝘆 𝘂𝗽 𝘁𝗼 𝟱𝟴% 𝗺𝗼𝗿𝗲 than those without, underscoring the critical role of ESG standards in promoting ecological balance as we observe Earth Day. We look forward to continuing our efforts in enhancing our ESG impact and contributing positively to our community and the planet. #Advaxia #Sustainability #EarthDay #ESG #CDMO
-
-
𝗔𝗱𝘃𝗮𝘅𝗶𝗮 𝗔𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝗛𝗶𝗴𝗵 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗥𝗮𝘁𝗶𝗻𝗴: 𝗔 𝗦𝘁𝗲𝗽 𝗙𝗼𝗿𝘄𝗮𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗼𝘂𝗿 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗝𝗼𝘂𝗿𝗻𝗲𝘆 We are proud to share that we’ve been awarded an impressive 𝗘𝗰𝗼𝗩𝗮𝗱𝗶𝘀 𝗿𝗮𝘁𝗶𝗻𝗴, marking a significant milestone in our commitment to sustainability. This certification is a testament to @Advaxia's dedication to 𝗘𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹, 𝗦𝗼𝗰𝗶𝗮𝗹, 𝗮𝗻𝗱 𝗚𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 (𝗘𝗦𝗚) 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲, an essential component of modern business practices, especially within the pharmaceutical and biotech industries where sustainable and ethical practices can greatly reduce environmental impact. Studies, including one from the Journal of Sustainable Finance & Investment, show that 𝗳𝗶𝗿𝗺𝘀 𝘄𝗶𝘁𝗵 𝘀𝘁𝗿𝗼𝗻𝗴 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁𝗮𝗹 𝗽𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗰𝗮𝗻 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲𝗶𝗿 𝗰𝗮𝗿𝗯𝗼𝗻 𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 𝗯𝘆 𝘂𝗽 𝘁𝗼 𝟱𝟴% 𝗺𝗼𝗿𝗲 than those without, underscoring the critical role of ESG standards in promoting ecological balance as we observe Earth Day. We look forward to continuing our efforts in enhancing our ESG impact and contributing positively to our community and the planet. #Advaxia #Sustainability #EarthDay #ESG #CDMO
-
-
Great start to the Advanced Therapies conference in London. Wonderful meeting with current and future clients at the conference. Stop by the Advaxia stand (26A) to say hello to our team and see how our decade plus of development, manufacturing and testing experience can benefit your viral vector program. Pictured below, right to left: Dr. Stefania DiMarco, Scientific Director and QP; Dr. Erik Noeldeke, newest member of the commercial team covering the UK/EU. #AdvancedTherapies2024 #Advaxia #ManufacturingExcellence #ViralVectorCDMO
-
-
We are just 2 weeks away from the Advanced Therapies conference in London, so contact our team to arrange a meeting to discuss your viral vector development, manufacturing or testing needs. Advaxia's Scientific Director and Qualified Person, Dr. Stefania DiMarco will be attending, so don't miss the opportunity to speak with an industry expert in the field of Advanced Therapies. We have limited meeting slots still available at the Advaxia stand (26A) so reach out to our team this week. https://lnkd.in/gX4aupER #advancedtherapies, #viralvectors, #genetherapy
-
We are delighted to announce that Erik Noeldeke, based in Munich, Germany, has been appointed as the Business Development Manager (Europe) for Advaxia. Erik brings a wealth of experience in the biopharmaceutical CDMO sector, making him a valuable addition to our team. Erik’s technical and business expertise will strengthen Advaxia's presence in the EU market. Advaxia, your trusted partner for fully integrated viral vector and vaccine development and manufacturing services. Advancing the next transformative biotherapeutics, propelled by a strong team of experts. Welcome to the team Erik! #Advaxia #Careers #CDMO #Vaccines #ViralVectors
-
-
Wishing you and your family a healthy and joyful holiday season from the Advaxia team. Buone Feste e Felice Anno Nuovo #HappyHolidays! #Seasonsgreetings #Advaxia
-
-
Advaxia is hiring! Come join an exceptional and growing team. Visit our career page on our website to view the full job description and submit your CV. #hiring Opening 1: Production Associate, Upstream Unit https://lnkd.in/gr4_RigX Opening 2: Production Associate, Downstream Unit https://lnkd.in/gqFThXJN
Job Position: Production associate, Upstream unit | Advaxia Biologics
https://advaxia.com